石四藥集團(02005.HK)一季度股東應占溢利減少59.5%至1.68億港元
格隆匯5月30日丨石四藥集團(02005.HK)公佈,集團銷售主要在中國進行,並以人民幣計值。按港元計,集團截至2025年3月31日止三個月之未經審核營業額較2024年同期減少36.9%至約11.36億港元,主要由於靜脈輸液(「靜脈輸液」)的銷量及安瓿注射液的未經審核營業額下降。集團截至2025年3月31日止三個月的未經審核毛利減少50.6%至約5.09億港元,其未經審核毛利率約為44.8%。截至2025年3月31日止三個月,集團未經審核公司股東應占溢利較2024年同期減少約59.5%至約1.68億港元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.